|1.||Rigas, Basil: 20 articles (06/2011 - 10/2003)|
|2.||Kashfi, Khosrow: 15 articles (01/2015 - 10/2003)|
|3.||Williams, Jennie L: 10 articles (07/2012 - 11/2003)|
|4.||Ouyang, Nengtai: 7 articles (06/2011 - 01/2004)|
|5.||Gao, Jianjun: 7 articles (04/2006 - 11/2003)|
|6.||Nath, Niharika: 6 articles (01/2015 - 10/2003)|
|7.||Kopelovich, Levy: 5 articles (06/2011 - 11/2003)|
|8.||Chen, Jie: 5 articles (10/2005 - 10/2003)|
|9.||Chattopadhyay, Mitali: 4 articles (01/2015 - 11/2009)|
|10.||Liu, Xiaoping: 4 articles (02/2008 - 10/2005)|
05/01/2011 - "Using a mouse model that develops MMR-deficient intestinal tumors that appear pathologically identical to LS/HNPCC, we show that ASA (400 mg/kg) and low-dose NO-ASA (72 mg/kg) increased life span by 18% to 21%. "
09/01/2008 - "Compared with the vehicle group, the necrotic area of tumors was higher in the m-NO-ASA-treated (61.0 +/- 2.7, P < 0.02) and p-NO-ASA (65.8 +/- 2.4, P < 0.001)-treated groups. "
04/15/2006 - "Nuclear factor-kappaB activation, absent in normal tissue, increased progressively (17-fold in cancer); NO-ASA suppressed it throughout and significantly in PanIN1B and PanIN2. "
08/01/2005 - "Our data indicate that NO-ASA is a highly promising agent for the prevention and/or treatment of cancer."
03/01/2005 - "Thus, the three positional isomers of NO-ASA differ in their metabolism and these differences correlate with their differential effects on cancer cell growth, underscoring the importance of positional isomerism in modulating drug effects."
|2.||Colonic Neoplasms (Colon Cancer)
06/15/2010 - "Protein levels of Hsp70, the product of HSPA1A, and fos were increased in p-NO-ASA-treated Jurkat T and HT-29 colon cancer cells in a dose-dependent manner. "
11/01/2007 - "An ongoing clinical trial is designed to determine whether NO-ASA can inhibit early stages of colon carcinogenesis in subjects at risk for colon cancer. "
11/22/2005 - "NO-ASA inhibits colon cancer cell growth several hundred times more potently than does ASA. "
10/01/2005 - "These findings indicate that NO-ASA profoundly inhibits both the expression and enzymatic activity of NOS2 and suggest that these effects may represent an important mechanism for the colon cancer chemopreventive effect of NO-ASA."
03/01/2005 - "Thus, positional isomerism is critical for the pharmacological properties of NO-ASA against colon cancer and it should be taken into consideration in rational drug design."
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/15/2011 - "As chronic lymphocytic leukemia (CLL) cells exhibit aberrantly active Wnt signaling, we investigated the effect of the para-isomer of NO-ASA on CLL cell survival in vitro and in a CLL-like xenograft mouse model. "
03/01/2012 - "Para-NO-aspirin (para-NO-ASA) is a novel drug with demonstrated efficacy against a number of solid tumors and most recently chronic lymphocytic leukemia. "
10/01/2011 - "The Antineoplastic Effect of Nitric Oxide-Donating Acetylsalicylic Acid (NO-ASA) in Chronic Lymphocytic Leukemia (CLL) Cells is Highly Dependent on its Positional Isomerism."
|4.||Breast Neoplasms (Breast Cancer)
11/15/2009 - "These studies suggest a targeted chemopreventive/chemotherapeutic potential for NO-ASA against breast cancer."
08/01/2005 - "In studies in vitro, NO-ASA inhibits the growth of colon, pancreatic, prostate, lung, skin, leukaemia and breast cancer cells, and is up to 6000-fold more potent than traditional ASA. "
01/01/2015 - "In vitro, we investigated anti-proliferation effects of NO-ASA (para- and meta-isomers) against ER(-) breast cancer cells MDA-MB-231 and SK-BR-23, effects on NF-κB signaling, and reactive oxygen species by standard techniques. "
07/01/2012 - "NO-ASA reduced the growth of several cell lines from colon, pancreas, skin, cervix and breast cancer much more potently than aspirin, with 24-h IC(50) values of 133-268 µM, while those of ASA were >1,000 µM. "
11/15/2009 - "We investigated the effect of para- and meta-positional isomers of nitric oxide-releasing aspirin (NO-ASA), and aspirin (ASA) on MCF-7 human breast cancer cell growth and beta-catenin/TCF signaling. "
07/01/2001 - "The area of gastric ulcer was determined by planimetry, the gastric blood flow (GBF) at ulcer margin was measured by H2 gas clearance method and mucosal release of ROS was quantified by measuring the chemiluminescence before and after the treatment with ASA or NO-ASA alone and ASA combined with vitamin C. "
12/01/2004 - "Previous studies have demonstrated that the gastric mucosa of diabetic rats is highly vulnerable to acute injury but the influence of nonsteroidal anti-inflammatory drugs (NSAID) and their new nitric oxide (NO) releasing derivatives of aspirin (NO-ASA) on the ulcer healing under diabetic conditions has been little studied. "
12/01/2004 - "In contrast to ASA, the treatment with NO-ASA failed to influence both, the ulcer healing and GBF at ulcer margin and significantly attenuated the plasma levels of IL-1beta, TNF-alpha and IL-10 as compared to those recorded in ASA- or rofecoxib-treated animals. "
07/01/2001 - "In this study the effect of NO-releasing aspirin (NO-ASA) and was compared with that of native aspirin applied with or without vitamin C on the healing of acetic acid ulcers. "
12/01/2004 - "We conclude that: 1) ulcer healing is dramatically impaired in experimental diabetes and this effect involves the fall in the gastric microcirculation at the ulcer margin and increased release of proinflammatory cytokines; 2) classic NSAID such as ASA and selective COX-2 inhibitors such as rofecoxib, prolong ulcer healing under diabetic conditions probably due to suppression of endogenous PG and the fall in the GBF at the ulcer margin suggesting that both COX isoforms, namely, COX-1 and COX-2, are important sources of PG during ulcer healing in diabetes; and 3) NO-ASA counteracts the impairment of ulcer healing in diabetic rats induced by ASA, mainly due to the release of NO that compensates for PG deficiency resulting in enhancement in the GBF at ulcer margin and suppression of cytokine release in the ulcer area."
|1.||N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester
|2.||Aspirin (Acetylsalicylic Acid)
|3.||Nitric Oxide (Nitrogen Monoxide)
|4.||Acetic Acid (Vinegar)
|6.||Caspase 3 (Caspase-3)
|7.||Ascorbic Acid (Vitamin C)
|1.||Heterologous Transplantation (Xenotransplantation)